An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy
- Has given written consent prior to any trial-related activity is performed. (A
trial-related activity is defined as any procedure that would not have been performed
during the normal management of the patient).
- Has completed the CS35 trial.
- Has been withdrawn from the CS35 trial.
- Has had end of trial visit in CS35 prior to approval of the CS35A protocol.
For detailed patient eligibility criteria for this clinical trial, please click here to show/hide